Yi-Husan Lin, MPH, and her colleagues identified double-blind placebo-controlled RCTs of antidepressants published between 2000 and 2020. The results in new generation antidepressant trials indicated that patients and assessors were unlikely to be able to judge treatment allocation. There was little evidence that the extent of unblinding biased the effect size estimates of new generation antidepressants.
The paper is open access at: https://authors.elsevier.com/sd/article/S2589537022002358.